News
PGNY
32.39
-0.64%
-0.21
Weekly Report: what happened at PGNY last week (0415-0419)?
Weekly Report · 3d ago
Progyny Price Target Maintained With a $46.00/Share by Truist Securities
Dow Jones · 04/17 17:31
Truist Securities Reiterates Buy on Progyny, Maintains $46 Price Target
Benzinga · 04/17 17:21
Weekly Report: what happened at PGNY last week (0408-0412)?
Weekly Report · 04/15 09:09
Weekly Report: what happened at PGNY last week (0401-0405)?
Weekly Report · 04/08 09:09
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?
Progyny, Inc. (NASDAQ:PGNY) is currently trading at a high price of US$35.67 on the NASDAQGS. The mid-cap stock is expected to double in the next few years. Progyny's price-to-earnings ratio is above the industry average for its sector. The company's share price movements can give investors a chance to buy at a lower price. Is PGNY currently undervalued, or is the stock still worth buying? We take a look at the company's outlook and value.
Simply Wall St · 04/03 10:45
Truist Financial Sticks to Its Buy Rating for Progyny (PGNY)
TipRanks · 04/02 11:25
Progyny, Inc.: Report of proposed sale of securities
Press release · 04/02 06:37
Weekly Report: what happened at PGNY last week (0325-0329)?
Weekly Report · 04/01 09:09
Weekly Report: what happened at PGNY last week (0318-0322)?
Weekly Report · 03/25 09:09
Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
Pete Anevski and Mark Livingston will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on March 19, 2024. Progyny, Inc. Is a transformative fertility, family building, and women's health benefits solution.
Barchart · 03/18 11:00
Weekly Report: what happened at PGNY last week (0311-0315)?
Weekly Report · 03/18 09:09
Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Seeking Alpha · 03/15 16:12
Truist Financial Reaffirms Their Buy Rating on Progyny (PGNY)
Truist Financial analyst Jailendra Singh reiterated a Buy rating on Progyny. The company’s shares closed yesterday at $36.69. The analyst consensus on ProGYny is a Strong Buy with an average price target of $47.14. Singh covers the Healthcare sector and has a 36.84% success rate on recommended stocks.
TipRanks · 03/14 11:25
Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference
Pete Anevski and Michael Sturmer will participate in a fireside chat at Barclays 26th Annual Global Healthcare Conference on March 12, 2024. Progyny, Inc. Is a transformative fertility, family building, and women’s health benefits solution.
Barchart · 03/11 11:00
Weekly Report: what happened at PGNY last week (0304-0308)?
Weekly Report · 03/11 09:09
Progyny: Long-Term Thesis Still Intact
Seeking Alpha · 03/09 09:30
Weekly Report: what happened at PGNY last week (0226-0301)?
Weekly Report · 03/04 09:09
Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher
Progyny (NASDAQ:PGNY) has a growing return on capital employed of 11%. The company has now broken into profitability. The company is using 5,031% more capital than it did five years ago. Progyny's ROCE is around the 10% rate of return for the Healthcare industry. The stock has declined 10% in the last three years.
Simply Wall St · 03/01 14:12
IVF Is Increasingly Big Business. Alabama's Ruling Could Actually Make It Bigger.
Alabama's court ruling on in-vitro fertilization has put a spotlight on IVF. The procedure has become more common in the U.S. Over the past decade. IVF companies like Progyny are one of a handful that offer fertility coverage for employers. The state of Alabama passed a bill Thursday to neutralize the effect of the ruling.
Barron‘s · 02/29 22:48
More
Webull provides a variety of real-time PGNY stock news. You can receive the latest news about Progyny, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.